Greenwich Lifesciences (NASDAQ: GLSI) net income
Greenwich Lifesciences reported a net loss of $19.4m for fiscal 2025; in fiscal 2024 it reported a net loss of $17.4m. Earnings per share were −$1.43.
Greenwich Lifesciences's best year of the last 7 was fiscal 2020. It reported a loss in 7 of those 7 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$19.4m | — | — | −$1.43 |
| 2024 | −$17.4m | — | — | −$1.34 |
| 2023 | −$8.9m | — | — | −$0.69 |
| 2022 | −$7.8m | — | — | −$0.61 |
| 2021 | −$4.6m | — | — | −$0.35 |
| 2020 | −$1.9m | — | — | — |
| 2019 | −$3.4m | — | — | — |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Greenwich Lifesciences net income compared with its sector
By net income for its latest fiscal year, Greenwich Lifesciences ranks 207th of the 501 US health care companies with a page on Celsmar.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 205th | RadNet | −$18.7m | −0.9% |
| 206th | SI-Bone | −$18.9m | −9.4% |
| 207th | Greenwich Lifesciences | −$19.4m | — |
| 208th | Heron Therapeutics | −$20.2m | −13.0% |
| 209th | Whitehawk Therapeutics | −$20.6m | −288.3% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Greenwich Lifesciences
- How much did Greenwich Lifesciences earn in fiscal 2025?
- Greenwich Lifesciences reported a net loss of $19.4m for fiscal 2025. In fiscal 2024 it reported a net loss of $17.4m.
- What are the earnings per share of Greenwich Lifesciences?
- They were −$1.43 in fiscal 2025, compared with −$1.34 in fiscal 2024.
- Where does Greenwich Lifesciences rank in its sector by net income?
- It ranks 207th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Greenwich Lifesciences come from?
- From the annual report (Form 10-K) that Greenwich Lifesciences files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Greenwich Lifesciences files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019. More on Greenwich Lifesciences: the Greenwich Lifesciences page · annual accounts · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.